A detailed history of Telemetry Investments, L.L.C. transactions in Affimed N.V. stock. As of the latest transaction made, Telemetry Investments, L.L.C. holds 200,000 shares of AFMD stock, worth $730,000. This represents 0.39% of its overall portfolio holdings.

Number of Shares
200,000
Previous 193,500 3.36%
Holding current value
$730,000
Previous $399,000 37.84%
% of portfolio
0.39%
Previous 0.51%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

BUY
$1.1 - $2.45 $7,150 - $15,925
6,500 Added 3.36%
200,000 $248,000
Q3 2022

Nov 17, 2022

BUY
$1.96 - $3.32 $6,860 - $11,620
3,500 Added 1.84%
193,500 $399,000
Q2 2022

Aug 15, 2022

BUY
$2.27 - $4.86 $113,500 - $243,000
50,000 Added 35.71%
190,000 $526,000
Q1 2022

May 16, 2022

SELL
$3.69 - $5.65 $37,859 - $57,969
-10,260 Reduced 6.83%
140,000 $612,000
Q4 2021

Feb 14, 2022

BUY
$5.37 - $7.07 $103,329 - $136,040
19,242 Added 14.69%
150,260 $829,000
Q3 2021

Nov 15, 2021

BUY
$5.54 - $7.51 $232,181 - $314,744
41,910 Added 47.03%
131,018 $810,000
Q2 2021

Aug 16, 2021

SELL
$7.78 - $11.4 $57,144 - $83,733
-7,345 Reduced 7.62%
89,108 $757,000
Q1 2021

May 17, 2021

SELL
$5.12 - $8.48 $313,344 - $518,976
-61,200 Reduced 38.82%
96,453 $763,000
Q4 2020

Feb 16, 2021

SELL
$3.16 - $7.03 $356,454 - $792,998
-112,802 Reduced 41.71%
157,653 $918,000
Q3 2020

Nov 16, 2020

BUY
$3.26 - $4.73 $134,263 - $194,805
41,185 Added 17.96%
270,455 $917,000
Q2 2020

Aug 14, 2020

SELL
$1.58 - $4.63 $149,310 - $437,535
-94,500 Reduced 29.19%
229,270 $1.06 Million
Q1 2020

May 15, 2020

SELL
$1.44 - $3.02 $147,339 - $309,003
-102,319 Reduced 24.01%
323,770 $512,000
Q4 2019

Feb 14, 2020

BUY
$2.25 - $3.07 $327,197 - $446,442
145,421 Added 51.81%
426,089 $1.17 Million
Q3 2019

Nov 14, 2019

SELL
$2.67 - $3.65 $1.08 Million - $1.47 Million
-403,371 Reduced 58.97%
280,668 $825,000
Q2 2019

Aug 14, 2019

BUY
$2.6 - $4.21 $855,501 - $1.39 Million
329,039 Added 92.69%
684,039 $1.96 Million
Q1 2019

May 15, 2019

SELL
$3.05 - $4.34 $214,713 - $305,527
-70,398 Reduced 16.55%
355,000 $1.49 Million
Q4 2018

Feb 14, 2019

BUY
$2.82 - $4.67 $673,187 - $1.11 Million
238,719 Added 127.88%
425,398 $1.32 Million
Q3 2018

Nov 14, 2018

SELL
$1.45 - $6.15 $385,665 - $1.64 Million
-265,976 Reduced 58.76%
186,679 $812,000
Q2 2018

Aug 14, 2018

SELL
$1.65 - $2.5 $152,369 - $230,862
-92,345 Reduced 16.94%
452,655 $747,000
Q1 2018

May 15, 2018

SELL
$1.25 - $2.65 $30,967 - $65,651
-24,774 Reduced 4.35%
545,000 $1.01 Million
Q4 2017

Feb 14, 2018

BUY
$1.23 - $2.3 $315,955 - $590,810
256,874 Added 82.09%
569,774 $741,000
Q3 2017

Nov 14, 2017

BUY
$1.95 - $2.25 $610,155 - $704,025
312,900
312,900 $704,000

Others Institutions Holding AFMD

About Affimed N.V.


  • Ticker AFMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,339,008
  • Market Cap $545M
  • Description
  • Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...
More about AFMD
Track This Portfolio

Track Telemetry Investments, L.L.C. Portfolio

Follow Telemetry Investments, L.L.C. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Telemetry Investments, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Telemetry Investments, L.L.C. with notifications on news.